Showing results (541-550 of 599) with videos related to

Sort By:
Pageof 60
ERJ Open Research|December 1, 2020
Environmental contamination related to SARS-CoV-2 in ICU patientsAlexandra Lomont, Marouane Boubaya, Warda Khamis, et al.
Molecular Nutrition & Food Research|October 12, 2021
Acid Hydrolysis of Gluten Enhances the Skin Sensitizing Potential and Drives Diversification of IgE Reactivity to Unmodified Gluten ProteinsAnne-Sofie Ravn Ballegaard, Laure Castan, Jeppe Madura Larsen, et al.
ACS Nano|August 28, 2010
Fine tuning of the relaxometry of γ-Fe2O3@SiO2 nanoparticles by tweaking the silica coating thicknessSonia L C Pinho, Giovannia A Pereira, Pierre Voisin, et al.
Plos One|November 28, 2023
Perceptions of self-monitoring dietary intake according to a plate-based approach: A qualitative studyMaryam Kheirmandparizi, Jean-Philippe Gouin, Celeste C Bouchaud, et al.
Thorax|February 5, 2021
Essential role of smooth muscle Rac1 in severe asthma-associated airway remodellingFlorian Dilasser, Lindsay Rose, Dorian Hassoun, et al.
AIDS (London, England)|October 17, 2018
Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trialRomain Palich, Jade Ghosn, Antoine Chaillon, et al.
European Journal of Medicinal Chemistry|September 22, 2018
Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical modelsCharles Dumontet, Guillaume Beck, Fabrice Gardebien, et al.
Travel Medicine and Infectious Disease|March 31, 2021
Imported schistosomiasis in Paris region of France: A multicenter study of prevalence and diagnostic methodsClaire Leblanc, Sophie Brun, Olivier Bouchaud, et al.
The Pediatric Infectious Disease Journal|August 3, 2017
Imported Schistosomiasis in Children: Clinical, Diagnostic Aspects And Outcome in 5 Tertiary Hospitals in FranceClaire Leblanc, Luu-Ly Pham, Patricia Mariani, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
Pageof 60